MEGLUMINE COMPOUND
- MEGLUMINE COMPOUND
- Dipigrafin®
- Oral Solution and Suspension
- 76%
- Bottle
- 120mL
Each 100mL Contains:
Meglumine Diatrizoate 66g
Sodium Diatrizoate 10g
Meglumine Diatrizoate 66g
Sodium Diatrizoate 10g
• Radiographic Exam of GI Tract Segments
Mechanism of Action
Contrast enhancement through GI tract
Pharmacokinetics
Excretion: Urine, feces
Contraindications
• Hypersensitivity to diatrizoate
Adverse Reactions
Tachyarrhythmia, Erythema of skin, Urticaria, Hyperthyroidism, Diarrhea, Nausea, Vomiting, Anaphylaxis, Dyspnea, Hypoxia
Major Drug Interactions
-
Warnings
• Aspiration may occur following oral administration that may result in serious complications
• May cause hypovolemia and hypotension due to fluid loss from hypertonic oral/rectal contrast solutions
Recommendations for Patient
-
Pregnancy Considerations
Category: C
Breastfeeding Considerations
Distributed in milk, use caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: Maybe acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Contrast enhancement through GI tract
Pharmacokinetics
Excretion: Urine, feces
Contraindications
• Hypersensitivity to diatrizoate
Adverse Reactions
Tachyarrhythmia, Erythema of skin, Urticaria, Hyperthyroidism, Diarrhea, Nausea, Vomiting, Anaphylaxis, Dyspnea, Hypoxia
Major Drug Interactions
-
Warnings
• Aspiration may occur following oral administration that may result in serious complications
• May cause hypovolemia and hypotension due to fluid loss from hypertonic oral/rectal contrast solutions
Recommendations for Patient
-
Pregnancy Considerations
Category: C
Breastfeeding Considerations
Distributed in milk, use caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: Maybe acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Send to other people